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http://www.biomedcentral.com/1472-6823/13/54RESEARCH ARTICLE Open AccessAllograft inflammatory factor 1 (AIF-1) is a new
human adipokine involved in adipose
inflammation in obese women
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and Ingrid Dahlman1Abstract
Background: Allograft inflammatory factor 1 (AIF-1) is a putative obesity gene. Our aim was to examine the
expression of AIF-1 in human white adipose tissue (WAT) in relation to obesity and metabolic phenotypes in
women.
Methods: WAT secretion of AIF-1 was determined in subcutaneous adipose tissue pieces in vitro by ELISA from 5
subjects. mRNA expression of AIF-1 was determined by RT-qPCR in the isolated cell fractions of adipose tissue
(n = 5-6 per group), in subcutaneous and visceral WAT pieces from non-obese (n = 12) and obese women (n = 23),
and in some subcutaneous WAT also before and after weight reduction (n = 10). Finally, adipose AIF-1 mRNA was
related to metabolic phenotypes in 96 subjects with a wide range of BMI.
Results: AIF-1 was secreted in a time dependent fashion from WAT. The major source of AIF-1 was WAT resident
macrophages. Expression of AIF-1 was similar in visceral and subcutaneous WAT and was two-fold increased in
obese women (P < 0.01). AIF-1 mRNA expression levels were normalized after weight reduction (P < 0.01). Expression
of AIF-1 was inversely correlated with insulin sensitivity as assessed by insulin tolerance test (KITT), and circulating
levels of adiponectin (P = 0.02), and positively correlated with insulin resistance as estimated by HOMA (=0.0042).
Conclusions: AIF-1 is a novel adipokine produced mainly by macrophages within human WAT. Its expression is
increased in obese women and associates with unfavourable metabolic phenotypes. AIF-1 may play a paracrine role in
the regulation of WAT function through cross-talk between macrophages and other cell types within the adipose tissue.
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In obese subjects, dysfunctional adipose tissue is believed
to contribute to metabolic disturbances including insulin
resistance. “Harmful” adipose tissue is characterized by
hypertrophic large fat cells, increased lipolysis, low grade
inflammation, and altered release of adipose hormons
i.e. adipokines [1-4]. Most adipokines display increased
release in obesity but some, such as adiponectin which
has beneficial metabolic effects in rodent models, are
decreased in obese subjects [5].* Correspondence: Silvia.Lorente-Cebrian@ki.se
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distribution, and reproduction in any mediumHuman adipose tissue is composed of several cell types
like adipocytes, endothelial and progenitor cells, and
monocytes/macrophages that interact to regulate adi-
pose tissue function [6]. Obesity is associated with infil-
tration of activated macrophages in adipose tissue,
which besides contributing to insulin resistance [4,7]
may also be directly involved in regulation of fat mass
[8]. Adipose tissue macrophages produce a number of
pro-inflammatory cytokines that promote adipose dys-
function and insulin-resistance [4,7]. To date, a number
of cytokines have been described to be secreted from dif-
ferent cells in human adipose tissue [9,10].
Allograft inflammatory factor-1 (AIF-1) is a protein
which participates in inflammatory responses and regu-
lates the function of macrophages [11]. Recent studiesCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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of inflammatory cytokines in mouse macrophages [12]
although its mechanism of action is incompletely under-
stood. AIF-1 has both been reported to be an intra-cellular
calcium-binding protein [13] and to be a secreted factor
[14,15], which may be linked to the presence of different
splice variants of AIF-1 gene in humans [11,12].
Recent findings suggest a role for AIF-1 in obesity. First,
a single nucleotide polymorphism (SNP) in the AIF-1 gene
region has been associated with body weight in a large
genome wide-association study [16]. Second, AIF-1−/−
mice are protected against diet induced obesity [17]. Based
on these findings, in this project we aim to explore the po-
tential function of AIF-1 in female adipose tissue by map-
ping AIF-1 expression and possible release from cells
within adipose tissue, as well as its relationship to obesity
and metabolic disturbances.
Methods
Participants and clinical evaluation
Subjects were either recruited by local advertisement or
from the outpatient clinic for treatment of obesity at the
local hospital. Obesity was defined as body mass index
(BMI) 30 kg/m2 or greater. All subjects were healthy except
for obesity and were free of medication. Participants were
investigated in the morning after an overnight fast. The
study was approved by the Research Ethics Committee at
Karolinska Institutet, South (Stockholm) and the Institu-
tional Research Board of INSERM and Toulouse University
Hospital. Written informed consent was obtained from all
participants. All the experimental procedures were con-
ducted under the provisions of the Declaration of Helsinki.
Examined cohorts are described in Table 1. All subjects
comprised women. Cohort 1 comprised five women (age
44 ± 3 yr, BMI 33 ± 11 kg/m2) that was used to evaluate
in vitro secretion of AIF-1 from abdominal adipose pieces.
WAT was obtained in connection with surgery for cos-
metic reasons or gastric bypass surgery for treating obes-
ity. These samples had been previously collected.
The cellular origin of AIF-1 was measured in cohort 2









1 5/0 44 ± 3 33 ± 11 N.A.
21 28/0 41 ± 2 29 ± 1 N.A.
3 (obese) 23/0 42 ± 10 44 ± 4 5.80 + 1.00
3 (non-obese) 12/0 40 ± 13 24 ± 2 4.82 + 0.42
4 10/0 39 ± 6 40 ± 6 5.61 + 0.67
5 96/0 39 ± 9 38 ± 7 5.51 + 1.06
1From each subject only one cell type could be isolated from adipose tissue. Five to
adipose tissue. In total, 28 subjects were used. 2KITT was available for 46 women. 3S
N. A. = Not available.for cosmetic reasons (age 41 ± 2 yr, BMI 29 ± 1 kg/m2).
Additional clinical data was not available for this cohort.
From each subject only one cell type could be isolated from
adipose tissue. Five to six subjects were used to quantify
each of the different sub-fractions of cells in adipose tissue.
In total, 28 subjects were used.
AIF-1 mRNA levels were quantified in subcutaneous and
visceral WAT in cohort 3 comprising 12 non-obese (age
40 ± 13 yr, BMI 24 ± 2 kg/m2) and 23 obese women (age
42 ± 10 yr, BMI 44 ± 4 kg/m2). The non-obese subjects were
operated for uncomplicated gallstone disease and the obese
underwent anti-obesity (bariatric) surgery (BMI > 40). Sub-
cutaneous adipose tissue from the surgical incision and
omental (visceral) adipose tissue were obtained at the be-
ginning of surgery. Only saline was given as an intravenous
infusion until adipose tissue was removed.
Subcutaneous WAT AIF-1 mRNA levels were further
investigated in cohort 4 comprising 10 obese women
(aged 39 ± 6 yr, BMI 40 ± 6 kg/m2) investigated before
and 2–4 yr after intense anti-obesity therapy with anti-
obesity surgery or behavioral modification when they
had reached a non-obese weight-stable state for at least
6 months (BMI 26 ± 3 kg/m2) [18]. Briefly, adjustable
vertical gastric banding was used as surgical treatment.
The patients were followed yearly and re-examined
when body weight had reached nadir two to four years
after operation and was stabilized for at least 6 months
according to self report (< 1 kg increase or decrease). Be-
havioral modification consisted of increasing motivation,
changing eating habits, enhancing physical activity and
regular 3 month follow ups for a year, when re-examination
took place. By then body was stabilized for at least one
month according to self report (< 1 kg increase or de-
crease). Weight loss was 22 ± 12% (mean ± SD) in the sur-
gery group and 14 ± 6% in the behavioural group. AIF-1
mRNA levels were related to metabolic phenotypes in co-
hort 5 comprising n = 96 women with a wide variation in
BMI (age 39 ± 9 yr, BMI 38 ± 7 kg/m2). In cohorts 4 and 5
biopsies of the subcutaneous abdominal WAT (0.5–2 g)
were obtained by needle aspiration under local anesthesia.








N.A. N.A. N.A. N.A.
N.A. N.A. N.A. N.A.
20.08 + 11.62 2.95 + 0.78 N.A. 5.13 + 0.75
8.45 + 2.91 N.A. N.A. 4.91 + 0.99
15.76 + 6.29 3.12 + 0.40 N.A. 4.83 + 0.75
14.50 + 9.09 3.54 + 1.372 12.04 + 5.853 5.00 + 0.95
six subjects were used to quantify each of the different sub-fraction of cells in
-Adiponectin was available for 37 women.
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Caucasian French women. WAT samples were brought to
the laboratory in saline, and one part was used immediately
for adipocyte experiments and another part was frozen in
liquid nitrogen. Unfortunately, it was not possible to recruit
enough male subjects to perform these clinical studies.
Insulin tolerance test (KITT) and HOMAIR
Insulin tolerance test was performed as previously de-
scribed [19]. Briefly, patients were examined in the
hospital at 8 a.m. after an overnight fast. Following a 30–
60 min rest, venous blood samples were taken for determi-
nations of fasting levels of glucose and plasma insulin.
Next, insulin was rapidly injected intravenously. After 2.5,
5, 7.5, 10, 15, 20, 25 and 30 min’s, blood glucose levels
were determined and plotted in a semilogaritmic graph
depicting blood glucose decrease along time. The rate
constant (k) derived from this plot represented the intra-
venous insulin tolerance (KITT). The homeostasis model
assessment for insulin resistance (HOMAIR) was calcu-
lated as fasting serum insulin (μU/ml) x fasting plasma
glucose (mmol/L)/22.5 [20].
Adipose morphology
Morphology of adipose tissue was calculated as previously
described [21]. Briefly, adipocytes and stroma-vascular
fraction (SVF), respectively, were isolated from adipose tis-
sue by collagenase digestion as previously described and
mean fat cell size determined [22]. Total fat mass was
measured by bioimpedance. We have fitted a curve, which
defines the relationship between mean adipocyte volume
and fat mass. The differences between observed mean adi-
pocyte volume in the present investigation and the ex-
pected volume as obtained from the curve fit at the
corresponding level of total body fat mass were calculated
separately for each of the 96 woman. The women were
classified as having either hyperplastic (negative deviation)
or hypertrophic (positive deviation) adipose tissue morph-
ology relative to the estimated average value for body fat.
The morphology values are quantitative: a larger absolute
positive or negative value reflects more pronounced
hypertrophy or hyperplasia, respectively, compared with a
small value.
Isolation of the different cell types from adipose tissue
The stroma-vascular fraction and adipocytes were ob-
tained after collagenase digestion and the different cell
types of the stroma-vascular fraction were obtained by
immunoselection and depletion as described previously
[23,24]. The following cell types were identified: endothe-
lial cells (CD34+/CD31+), fraction containing cells with
capacity to differentiate into fat cells (progenitor cells;
CD34+/CD31-), macrophages (CD34-/CD14+), and
T lymphocytes (CD34-/CD14-/CD31+) [6].RNA preparation and cDNA synthesis
Adipose tissue pieces (300 mg) or 200 μL isolated cells
were kept at −70°C for subsequent RNA extraction using
the RNeasy minikit (QIAGEN, Hilden, Germany). RNA
samples were treated with ribonuclease-free deoxyribo-
nuclease (QIAGEN). The RNA concentration was deter-
mined using spectrophotometer and the quality of RNA
was confirmed using an Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA). One microgram of RNA was
reverse transcribed to cDNA using the Omniscript reverse
transcriptase kit (QIAGEN) and random hexamer primers.
For qPCR analysis on the distinct cell types of human adi-
pose tissue, mRNA were extracted from macrophages,
lymphocytes, adipocytes, endothelial cells, and progenitor
cells isolated from human AT as previously described [6].
RNA was reverse-transcribed using the “Superscript II” kit
(Invitrogen, Cergy-Pontoise, France).
Quantitative real-time PCR
Adipose tissue AIF-1 mRNA and the internal control gene
18S were quantified using the SYBR Green-based technol-
ogy. Primer pairs were designed to span exon-intron
boundaries. The following primers were used for specific
mRNA quantification: 5’ GATGATGCTGGGCAAGA
GAT-3’ and 5’ CCTTCAAATCAGGGCAACTC-3’ for
AIF-1; 5’ CACATGGCCTCCAAGGAGTAAG-3’ and 5’
CCAGCAGTGAGGGTCTCTCT-3’ for 18S [25]. 5 ng of
cDNA were mixed with gene-specific primers (final con-
centration 300 nM) and IQ SYBR green supermix (Bio-Rad
Laboratories, Hercules, CA) PCR was performed with an
iCycler IQ (Bio-Rad Laboratories). A direct comparative
method was used for data analysis, i.e. 2(Ct target calibrator - Ct
target sample)/2(Ct 18S calibrator - Ct 18S sample). The PCR effi-
ciency in all runs was close to 100% and all samples were
run in duplicate.
For qPCR analysis on the distinct cell types of human
adipose tissue AIF-1 primers were from Applied Biosys-
tems (Courtaboeuf, France Hs 00610419 g1). The amplifi-
cation reaction was performed in duplicate on 15 ng
cDNA samples in a final volume of 20 μL in 96-well reac-
tion plates (Applied Biosystems) in a GeneAmp 7500 de-
tection system. All reactions were carried out under the
same conditions: 50°C for 2 min, 95°C for 10 min, 40 cycles
of 95°C for 15 sec and 60°C for 1 min. Results were ana-
lyzed with the GeneAmp 7500 software and all the values
were normalized to the levels of 18S rRNA (Applied
Biosystems).
Protein measurements
WAT pieces (300 mg in 3 mL medium) were incubated
for different periods of time as described [26]. Briefly, adi-
pose tissue samples from cohort 1 were minced in small
pieces and visible vessels and coagulation particles were















Figure 1 AIF-1 secretion from WAT in vitro. Pieces of WAT
(300 mg) were incubated in Krebs-Ringer phosphate buffer (pH 7.4)
supplemented with 40 g/liter of defatted bovine serum albumin and
1 g/liter of glucose (3 mL) and the concentration of AIF-1 in medium
was determined by ELISA, see “Protein measurements” section for
details (cohort 1; n = 5 women, 44 ± 3 years, BMI 33 ± 11 kg/m2).

































Figure 2 AIF-1 mRNA levels in the different cell fractions in
human WAT (cohort 2; n = 5-6 subjects per cell fraction, n = 28
subjects in total, see “Participants and clinical evaluation”
section for details). Statistical differences were analyzed by
unpaired t-test and related to the adipocyte fraction. ***P < 0.001 vs.
adipocyte fraction.
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phate buffer (pH 7.4) supplemented with 40 g/liter of de-
fatted bovine serum albumin and 1 g/liter of glucose.
WAT samples were incubated for 3 hours at 37°C in a
shaking water bath, with air as the gas phase. After 1, 2
and 3 hours, 2 mL of the medium was removed and fro-
zen in liquid nitrogen. Medium was saved at −70°C for
later determination of AIF-1 levels by ELISA (Catalog no.
E92288Hu; USCNK Life Science Inc., China), according to
the manufacturer’s instructions. Values were expressed as
picograms per milliliter. Serum levels of adiponectin were
measured using a RIA method (Linco Research, Inc., St.
Charles, MO) and were expressed as micrograms
per milliliter.
Statistical analysis
Unpaired or paired t test (two sided) was used to compare
mRNA levels between two groups. Values are mean ± SD.
We used simple regression and multiple regression with
BMI as covariate to examine relationships between quanti-
tative variables. Differences were considered as statistically
significant at p < 0.05. The statistical analyses were per-
formed using Statview software (version 5.01; SAS Insti-
tute, Cary, NC).
Results
AIF-1 is secreted from pieces of adipose tissue
We first wanted to assess whether AIF-1 was secreted
from human adipose tissue. Adipose tissue pieces from
women in cohort 1 were incubated in vitro as described
[27] and secretion of AIF-1 was measured in the condi-
tioned medium by ELISA. AIF-1 levels accumulated in
the media along the 3 h-experimental period (Figure 1)
demonstrating that AIF-1 was secreted in a time
dependent-manner from WAT pieces in all of the 5 ex-
periments. This defines AIF-1 as a novel adipokine.
AIF-1 is mainly produced by adipose-tissue macrophages
We next investigated the cellular source of AIF-1 in human
WAT using cohort 2 (age 41 ± 2 yr, BMI 29 ± 1 kg/m2).
Our results show that the stroma-vascular fraction was the
major source of AIF-1 mRNA in WAT. Highest levels of
AIF-1 were observed in the CD34-/CD14+ cells, which
contain macrophages (P < 0.001; Figure 2). Very low levels
of AIF-1 mRNA were detected in isolated adipocytes;
mRNA levels in lymphocytes, endothelial and progenitor
cells were in between those in adipocytes and macrophages.
AIF-1 mRNA expression in human adipose tissue in
relationship to obesity
WAT mRNA levels of AIF-1 were increased about two-
fold in obese as compared to non-obese women from
cohort 3 in both abdominal subcutaneous and visceral
fat depots, (P < 0.01; Figure 3a and 3b). Neither age, noradipose tissue depot influenced AIF-1 mRNA expression
(values not shown). Furthermore, AIF-1 mRNA levels in
subcutaneous WAT were normalized in obese women
from cohort 4 following marked long term weight loss
(P < 0.01; Figure 3c). To assess whether the association be-
tween AIF-1 mRNA levels and obesity was related to in-
creased macrophage infiltration into adipose tissue, we
wished to correlate AIF-1 levels to a macrophage marker.
Integrin alpha-X (ITGAX) is a gene specific for proinflam-
matory macrophages [28]. We used a previously published
global microarray-based gene expression profile on ab-
dominal subcutaneous adipose tissue from obese and lean
women (n = 56) [28] to show that AIF-1 and ITGAX levels













































































Figure 3 AIF-1 mRNA levels in relation to adiposity in (a) abdominal subcutaneous WAT, and (b) visceral WAT (cohort 3, n = 23 obese
women, 42 ± 10 years, 44 ± 4 kg/m2, n = 12 non-obese women, 40 ± 13 years, 24 ± 2 kg/m2), and (c) in abdominal subcutaneous WAT
of obese women (cohort 4, n = 10, 39 ± 6 years, 40 ± 6 kg/m2) before and 2–4 years after intense anti-obesity therapy when they had
reached a non-obese weight-stable state. Statistical differences were analyzed by un-paired (a and b) or paired t-test (c). **P < 0.01.
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unfavourable clinical metabolic parameters
We next wanted to investigate whether AIF-1 expression
in WAT was associated with clinical parameters related to
insulin sensitivity in a large cohort of women (cohort 5).
AIF-1 was correlated to BMI and not age in this cohort
(Table 2). In multiple regression with BMI and AIF-1
mRNA levels as independent factors, we found that WAT
AIF-1 expression was independently correlated with insu-
lin resistance as determined by HOMAIR (partial r = 0.369,
P = 0.0042) in this cohort of women. In a subgroup of
women insulin sensitivity as estimated by the short insulin
tolerance test (KITT) and circulating levels of adiponectin
had been quantified. In this group of patients WAT AIF-1
expression was inversely and independently of BMI
(Table 2) correlated with insulin sensitivity as estimated by
the short insulin tolerance test (KITT) (partial r = −0.396,Table 2 Regression of clinical and metabolic phenotypes on A
AIF-1
Regressor r -value
Age (years, n = 96) 0.056
BMI (kg/m2, n = 96) 0.44
KITT (rate constants, n = 46)3 −0.378
Adiponectin (μg/ml, n = 37)4 −0.375
Adipose morphology (delta, n = 96)5 0.274
Fat cell volume (n = 96)6 0.456
Log HOMA (n = 93)7 0.497
1Simple regression. 2Multiple regression with BMI together with one other variable at a
significant when examined together with KITT, fat cell volume or HOMA (partial r betw
(partial r = 0.44; p = 0.004) 3Insulin tolerance test was performed in patients after an ov
25 and 30 min’s, blood glucose levels were determined and plotted in a semilogaritmic
from this plot represented the intravenous insulin tolerance (KITT). 4Serum levels of ad
adipocyte volume and total body fat determines adipocyte morphology. Delta is the d
the expected volume (as obtained from the curve fit) at the corresponding level of tot
values are quantitative: a larger absolute positive or negative value (delta) reflects mor
value, see Morphology in methods section for details. 6Adipocytes were isolated from
size determined as described in reference [21]. 7The homeostasis model assessment fo
fasting plasma glucose (mmol/L)/22.5.P = 0.017, Figure 4a), and circulating levels of adiponectin
(partial r = −0.334, P = 0.023, Figure 4b). Finally, WAT
AIF-1 expression was independently of BMI associated
with fat cell volume (partial r = 0.396, P = 0.0041; Table 2),
but not adipose morphology (values not shown). In the
multiple regression analysis (Table 2), BMI became non-
significant as regressor in the presence of all variables
except adiponectin.
Discussion
Recent proteomics studies suggested that fat cells or other
cells within WAT have the potential to generate hundreds
of adipokines [10,29,30]. However, only a few of these can-
didates have been validated as being true adipokines (time
dependent secretion) and the regulation or function is un-
known for most of the potential adipokines [10]. In the
present study, we present evidence that AIF-1 is releasedIF-1 expression
1 AIF-12








time as independent variables. In the multiple regression, BMI became non-
een 0.04 and 0.18). However it remained significant together with adiponectin
ernight fast. Insulin was rapidly injected intravenously. After 2.5, 5, 7.5, 10, 15, 20,
graph depicting blood glucose decrease along time. The rate constant (k) derived
iponectin were measured using a RIA method. 5The relationship between mean
ifference between observed adipocyte volume in the present investigation and
al body fat mass were calculated separately for each woman. The morphology
e pronounced hypertrophy or hyperplasia, respectively, compared with a small
adipose tissue by collagenase digestion as previously described and mean fat cell





















Relative AIF-1 mRNA expression
a b
Figure 4 Correlation between AIF-1 mRNA expression and (a) rate constant of KITT (a subset of cohort 5, n = 46 women, 39 ± 9 years,
39 ± 7 kg/m2) and (b) S-Adiponectin (subset of cohort 5, n = 37 women , 40 ± 8 years, 37 ± 7 kg/m2). Statistical outcomes are displayed
in Table 2.
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ing that AIF-1 is an adipokine in humans. It has previously
been shown that the protein expression of AIF1 reflects
mRNA levels [31]. In subsequent studies investigating clin-
ical correlates of adipose AIF-1 we therefore relied on
mRNA measurements. We showed that adipose AIF-1 is
regulated by changes in body fat mass. AIF-1 gene expres-
sion was markedly up-regulated in obese women. These
findings support previously published data from genetic
studies in humans [16] and mice [17], and give further sup-
port to the notion that AIF-1 is an obesity-related gene.
Adipose tissue is composed by a number of different cell
types; only around 50% are adipocytes our data suggest that
the major source of AIF-1 in human adipose tissue is mac-
rophages, and that the levels of AIF-1 mirror the levels of
proinflammatory macrophages in adipose tissue as assessed
by the marker ITGAX. We therefore speculate that in
WAT, AIF-1 may contribute to the regulation of adipose in-
flammation. Increases in fat mass prompt accumulation of
macrophages in WAT [4,7] which produce a number of
chemokines and cytokines [27]. It has been described that
AIF-1 stimulates secretion of inflammatory mediators from
mouse macrophages [12], indicating that it might be one
mediator contributing to WAT inflammation. However, at
the present time, the physiological role and mechanism of
action of AIF-1 in human WAT remains elusive.
We also observed that AIF-1 expression was associated
to a negative metabolic profile (i.e. parameters of insulin
resistance). This is in agreement with the finding that adi-
pose AIF-1 is strongly associated with the macrophage
marker ITGAX. A low grade of local adipose inflamma-
tion has been linked to insulin resistance [32]. We do not
know whether AIF-1 is just a marker of adipose inflamma-
tion or is directly involved in regulation of adipose insulin
sensitivity, maybe by regulating the local production ofadipokines in adipose tissue, e.g. by inhibiting production
of adiponectin. Interestingly, Fukui M et al., have recently
shown that the serum AIF-1 concentrations are positively
correlated with an unfavorable metabolic profile with in-
creased fasting plasma glucose and triglycerides, and in-
versely correlated with high-density lipoprotein cholesterol
levels [33]. In a different study, these authors also suggested
that AIF-1 could be a marker for diabetic nephropathy as
well as activated macrophages [34]. However, we have not
investigated whether adipose tissue secreted AIF-1 is in-
volved in systemic inflammation.
Several studies have been published where AIF-1 function
was studied by plasmid over-expression in different human
cell lines [35,36]. However, this was not physiologically feas-
ible in our experimental settings as we observed that AIF-1
is hardly produced in adipocytes. Moreover, co-culture of
macrophages/adipocytes might have been an alternative
but was out of the scope of the present study. Another limi-
tation of the present study is that all experiments were car-
ried out in women only. Therefore, evaluation of whether
observed effects are also observed in male WAT remains a
key issue to be addressed in future. We do not know levels
of gender hormones in studied subjects. However, the fact
that age had no influence on AIF-1 levels argues against
any major influence of menopause on AIF-1. Whether
there is an influence of menstrual cycle date on the results
presented in this study is very difficult to assess.
Conclusion
In conclusion, AIF-1 is a novel human adipokine pro-
duced mainly by macrophages within WAT that might
exert some paracrine effects on fat cells. Adipose AIF-1
is increased in obesity and might participate in the regu-
lation of adipose tissue inflammation and, in turn, insu-
lin resistance.
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